Entering text into the input field will update the search result below

Artelo Biosciences Chart Indicates Possible Big Move Upwards

StocksnSox profile picture
StocksnSox's Blog
Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.


  • Artelo Biosciences is a biotech company and a Marijuana play.
  • This play has a considerable amount of warrants between $0.75 and $7 a share.
  • The gap between $0.75 and $7 is obviously rather large, so we think based on this and the bullish chart, we could see a move to over $2.
  • The company actually holds a license to legit technology.

Our view on Artelo Biosciences (ARTL) is mainly a trade opportunity for now, in which after giving a basic overview of its tech platform, we will show our bullish trade thesis on the chart. In a nutshell, this company has a lot of warrants tha strike at $0.75 cents and $7 a share. We think this gives this play a ton of room for upside as we have seen many of these "cheapies" run a ton over the past year. Please note, we aren't making an investment thesis here, only a trading one for the short term.

ARTL has 3 programs in its pipeline: ART27.13 – a CB1/CB2 agonist picked up from AstraZeneca (AZN) for the treatment of Cancer Anorexia Cachexia Syndrome (CACS), ART26.12 – A Fatty Acid Binding Receptor 5 (FABP5) inhibitor studied for the treatment of prostate and breast cancers, and ART12.11 a co-crystal formulation of Cannabidiol and Trimethoprim for PTSD. Of these, we are particularly interested in the ART26.12 preclinical program licensed from Stony Brook University in NY. The program is supported by two grants – $3.8M from the NIH and $4.2M from the NCI.

FABP5 is a compelling target, particularly in the metabolically aggressive TNBC subtype, where it has been demonstrated to be a strongly negative prognostic indicator and can promote metastatic escape. Interestingly, this study found extremely strong correlation between EGFR (which is highly expressed in TNBC) and high FABP5 expression (P < 0.001). The authors claim FABP5 stabilizes EGFR and prevents its proteasomal degradation. An alternative pathway proposed for FABP5 in TNBC is through the competition with CRABP2 for the binding of retinoic acid, preferentially signaling PPAR-beta over RAR and promoting tumor growth and resistance. Patients with a high tumoral CRABP2/FABP5 had significantly longer overall survival (P = 0.0051).

In prostate cancer cell lines, the compounds developed by Stony Brook have demonstrated both single agent and synergistic activity with docetaxel, a commonly used chemotherapy for both breast and prostate cancers. Though the program is still early, the company has expressed interest in accelerating its development and running IND enabling studies next year. It is a compelling speculative target with dramatic upside from current valuations.

Technical Chart analysis (click on chart to enlarge and view in high resolution):

ChartWe have added white lines to explain where we think this chart is headed. The stock right now is right at the first warrant strike of $0.75. As we can see, the pps has been steadily rising with 6 valleys marked in the white u shapes. Accumulation/distribution is trending in the right direction with bollinger bands indicating a hard break is coming up here shortly in our opinion. However, we need to pivot away from the $0.78 range with volume in order to get the big break out we are looking for.

We also mark the green volume days as well, showing how the volume trend seems to us to be a subtle short cover underneath the $0.75 first warrant level. We think this play has several rally price points up to $2.50 a share.

First level would be right at the 200 SMA of around $0.98 cents. If the company releases a significant PR, then we think we can hit the next level of $1.20 to as high as $2.50.

Downside we see here would be around $0.55.

This one is an interesting play here as the so-called "Pot Stocks" have been on a nice roll lately. While this one is potentially a lot more than just a pot stock, it's basically more know for as such.

Perhaps once the company can straighten out the warrant coverage and financing, we could like it more than just a trade because its tech is very interesting with strong speculative rationale. However, for now we see it strictly as a short term upside breakout trade.

Levels below:

Consider a stop under $0.55.

Consider adding over $0.65

Sell level 1, $0.98

Sell level 2 $1.20

Sell level 3, $1.48

Sell level 4, over $2.

As mentioned above, there are also warrants at $7, so the warrant holders might try to play a 'middle trade' between $0.75 and $7 which could take this one to near $3.

If we get the rally here, consider a rising stop and trail selling.

On watch for upcoming biotech catalysts: (OTC:CALA) (GTHX)

Analyst's Disclosure: I am/we are long ARTL, CALA.

Disclaimer: this article is intended for informational and entertainment use only, and should not be construed as professional investment advice. They are our opinions only. Trading stocks is risky - always be sure to know and understand your risk tolerance. You can incur substantial financial losses in any trade or investment. Always do your own due diligence before buying and selling any stock, and/or consult with a licensed financial adviser.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.